Marvell’s Lumentum Deal Sparks Analyst DowngradesMarvell Technology, Inc.BATS:MRVLKalaGhaziMarvell Technology (NASDAQ:MRVL) drew two notable downgrades after agreeing to acquire Lumentum in an all-stock deal, a transaction that has forced investors to reconsider both the strategic upside and the near-term risks. BofA analyst Vivek Arya downgraded Marvell to Neutral from Buy and cut his price target to $225 from $400. TD Cowen also moved to the sidelines, downgrading the stock to Hold from Buy and reducing its target to $175 from $350. The downgrades came after the deal announcement, which valued Lumentum at about $115 billion including debt and sent Marvell shares down roughly 13%. The strategic logic behind the deal is relatively straightforward. Marvell designs the chips and networking gear that move data inside AI data centers, while Lumentum makes optical components that carry that data as light. Combining the two would give Marvell a broader position in the optical connectivity layer of AI infrastructure—an area that could become more important as AI clusters grow larger and data movement becomes a bigger bottleneck. In that reading, the acquisition is a way for Marvell to capture a larger share of AI-related spending rather than remaining concentrated in its existing chip and networking footprint. But the financing structure is central to the skepticism. Because Marvell is paying with its own stock, current shareholders will own a smaller slice of a larger company. That dilution matters, especially when the market is trying to value the combined business before it has demonstrated how the two product lines will fit together. The roughly 13% drop in Marvell shares suggests investors are immediately discounting the deal’s execution risk, dilution, and the possibility that Marvell is paying a high price for optical exposure at a time when AI infrastructure valuations are already stretched. The analyst reaction is not unanimous. UBS reiterated its Buy rating and $350 target on November 3, signaling that at least one major firm still sees the combination as strategically compelling. Cantor Fitzgerald stayed at Neutral but with a lower $225 target. That split is instructive: it shows investors and analysts are weighing whether the optical business gives Marvell a meaningfully bigger share of AI spending against whether the deal adds integration risk, complicates the product roadmap, and dilutes existing holders before the benefits are visible. Investors will also be watching how the two companies combine their product lines. Marvell’s existing strengths in data-center chips and networking gear will need to mesh with Lumentum’s optical components in a way that produces real cross-selling or bundled offerings rather than just a larger, more complex company. The integration question is especially important because the skeptics’ case predates the deal—as previously laid out, the few analysts without a Buy rating were already focused on valuation, execution, and the durability of Marvell’s AI growth outlook weeks before the Lumentum announcement. The deal has not created that debate so much as sharpened it: the bull case is that optics expand Marvell’s AI opportunity; the bear case is that dilution and integration risk arrive before the payoff is proven.